S'abonner

Reduction of Coronary Flow Velocity Reserve as the Main Driver of Prognostically Beneficial Coronary Revascularization - 02/01/25

Doi : 10.1016/j.echo.2024.09.011 
Lauro Cortigiani, MD a, , Nicola Gaibazzi, MD b, Quirino Ciampi, MD, PhD c, Fausto Rigo, MD d, Domenico Tuttolomondo, MD b, Francesco Bovenzi, MD a, Dario Gregori, PhD e, Scipione Carerj, MD f, Mauro Pepi, MD g, Patricia A. Pellikka, MD h, Eugenio Picano, MD, PhD i
on behalf of the

Stress Echo 2030 study group

a Cardiology Division, San Luca Hospital, Lucca, Italy 
b Cardiology Department, Parma University Hospital, Parma, Italy 
c Cardiology Division, Fatebenefratelli Hospital, Benevento, Italy 
d Cardiology Division, Villa Salus Hospital, Mestre, Italy 
e Biostatistics, Epidemiology and Public Health Unit, Padova University, Padova, Italy 
f Divisione di cardiologia, Policlinico Universitario, Università di Messina, Messina, Italy 
g Centro Cardiologico Monzino, IRCCS, Milan, Italy 
h Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota 
i Cardiology Clinic, University Center Serbia, Medical School, University of Belgrade, Belgrade, Serbia 

Reprint requests: Lauro Cortigiani, MD, Ospedale San Luca, Via Guglielmo Lippi Francesconi, 55100 Lucca, Italy.Ospedale San LucaVia Guglielmo Lippi FrancesconiLucca55100Italy

Abstract

Background

Regional wall motion abnormality (RWMA) can be absent during stress echocardiography (SE) in patients with chronic coronary syndromes (CCS) and angiographically significant coronary artery disease (CAD) despite a reduction of coronary flow velocity reserve (CFVR).

Objectives

To assess the value of a physiology-driven approach, based on CFVR, to coronary revascularization in patients with physiologically and anatomically significant disease of the left anterior descending (LAD) coronary artery.

Methods

In a 3-center, observational study with retrospective analysis of prospectively acquired data, 749 patients with CCS, CFVR of the LAD ≤2.0, and ≥50% diameter stenosis of the LAD were enrolled. All patients were evaluated with dipyridamole (0.84 mg/kg in 6’) SE. Patients were followed for 6.4 ± 4.5 years for the outcome of all-cause death.

Results

Inducible RWMA was present in 295 patients (39%). Coronary flow velocity reserve was lower in patients with inducible RWMA compared to those without (1.51 ± 0.28 vs 1.65 ± 0.25; P < .001). Coronary revascularization was performed in 514 (69%) patients (388 with percutaneous coronary intervention, 126 with coronary artery bypass surgery). Of them, 226 exhibited inducible RWMA and 288 exhibited isolated reduction of CFVR. During the follow-up, 185 (25%) deaths occurred. The 10-year survival in the entire study population was 70%. The survival at 10 years was markedly lower in conservatively treated patients compared to invasively treated patients (53 vs 76%; P < .0001), with no significant difference between those with solitary reduction of CFVR and reduction of CFVR accompanied by concurrent inducible RWMA. Propensity score–weighted all-cause mortality risk was significantly higher for conservative than for invasive strategy (propensity score adjusted hazard ratio = 2.12; 95% CI, 1.51–2.96; P < .0001).

Conclusions

In patients with CCS and physiologically and anatomically significant LAD disease, coronary revascularization driven by a reduction in CFVR is accompanied by a prognostic benefit independently of the presence of inducible RWMA.

Le texte complet de cet article est disponible en PDF.

Central Illustration

Middle upper panel: The propensity score–weighted Kaplan-Meier survival curves in invasively and conservatively treated patients with reduction of CFVR of the LAD. Middle lower panel: The annualized death rate stratified on the basis of the presence or absence of inducible RWMA in the conservative strategy and invasive strategy groups. Right upper panel: The SE inclusion criterion: a reduced CFVR in the LAD. Right lower panel: The angiographic inclusion criterion: a significant stenosis of the LAD (indicated by a yellow arrow).



Central Illustration : 

Middle upper panel: The propensity score–weighted Kaplan-Meier survival curves in invasively and conservatively treated patients with reduction of CFVR of the LAD. Middle lower panel: The annualized death rate stratified on the basis of the presence or absence of inducible RWMA in the conservative strategy and invasive strategy groups. Right upper panel: The SE inclusion criterion: a reduced CFVR in the LAD. Right lower panel: The angiographic inclusion criterion: a significant stenosis of the LAD (indicated by a yellow arrow).


Central IllustrationMiddle upper panel: The propensity score–weighted Kaplan-Meier survival curves in invasively and conservatively treated patients with reduction of CFVR of the LAD. Middle lower panel: The annualized death rate stratified on the basis of the presence or absence of inducible RWMA in the conservative strategy and invasive strategy groups. Right upper panel: The SE inclusion criterion: a reduced CFVR in the LAD. Right lower panel: The angiographic inclusion criterion: a significant stenosis of the LAD (indicated by a yellow arrow).

Le texte complet de cet article est disponible en PDF.

Highlights

Transthoracic Doppler echocardiography evaluates coronary flow velocity.
Mid-distal segment of the LAD coronary artery is the target.
Anatomy-driven coronary revascularization gives no survival benefit.
Wall motion abnormalities–driven coronary revascularization gives no survival benefit.
Physiology-driven coronary revascularization gives substantial survival benefit.

Le texte complet de cet article est disponible en PDF.

Keywords : Coronary flow velocity reserve, Coronary revascularization, Dipyridamole, Left anterior descending artery, Prognosis

Abbreviations : CABG, CAD, CCS, CFVR, HR, LAD, LV, LVEF, PCI, RWMA, SE, WMSI


Plan


 Travel, publication, and infrastructural funding came from Società Italiana di Ecocardiografia e Cardiovascular Imaging.
 Rosa Sicari, MD, PhD, served as guest editor for this report.


© 2024  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 38 - N° 1

P. 24-32 - janvier 2025 Retour au numéro
Article précédent Article précédent
  • Cardiac Function and Functional Capacity in Patients With Long COVID: A Comparison to Propensity-Matched Community Controls
  • Thomas H. Marwick, Noah Wexler, Joel Smith, Leah Wright, Felicia Ho, Marc Oreto, Ashleigh-Georgia Sherriff, Richard Allwood, Yusuke Sata, Stefano Manca, Erin Howden, Quan Huynh
| Article suivant Article suivant
  • Three-Dimensional Transthoracic Echocardiography for Semiautomated Analysis of the Tricuspid Annulus: Validation and Normal Values
  • Juan I. Cotella, Alexandra Blitz, Alexandra Clement, Michele Tomaselli, Denisa Muraru, Luigi P. Badano, Natascha Sauber, Adria Font Calvarons, Markus Degel, Agnieszka Rucki, Michael Blankenhagen, Megan Yamat, Marcus Schreckenberg, Karima Addetia, Federico M. Asch, Victor Mor-Avi, Roberto M. Lang, WASE Investigators, Aldo D. Prado, Eduardo Filipini, Ricardo E. Ronderos, Agatha Kwon Samantha Hoschke-Edwards, Gregory M. Scalia, Tania Regina Afonso, Ana Clara Tude Rodridugues, Babitha Thampinathan, Maala Sooriyakanthan, Wendy Tsang, Yingbin Wang, Yu Zhang, Tiangang Zhu, Zhilong Wang, R. Alagesan, S. Balasubramanian, R.V.A. Ananth, Vivekanandan Amuthan, Manish Bansal, Ravi R. Kasliwal, Azin Alizadehasl, Anita Sadeghpour, Eduardo Bossone, Tomoko Nakao, Takayuki Kawata, Megumi Hirokawa, Naoko Sawada, Masao Daimon, Yousuke Nabeshima, Masaki Takeuchi, Pedro Gutierrez Fajardo, Kofo O. Ogunyankin, Edwin S. Tucay, Hye Rim Yun, Seung Woo Park, Ji-won Hwang, Mark J. Monaghan, James N. Kirkpatrick, Tatsuya Miyoshi

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.